One‐year follow‐up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry

Introduction/Aims We studied the progression of myasthenia gravis (MG) disease burden and medication adjustment among MG Patient Registry participants. Methods Participants diagnosed with MG (age ≥18 years), registered between July 1, 2013 and July 31, 2018 and completing both 6‐ and 12‐month follow‐up surveys, were included in this investigation. Participants were grouped into high‐burden (Myasthenia Gravis Activity of Daily Living scale [MG‐ADL] score ≥6) and low‐burden (MG‐ADL 20%) at 6 months significantly increased the likelihood of achieving MSE at 12 months (P = .0004). Discussion In both groups, but more so in the high‐burden group, patients infrequently achieved MSE after 1 year of MG treatment. Baseline low disease burden, improvement at 6 months and no pyridostigmine use were associated with a higher likelihood of MSE at 12 months. See Editorial on pages 382‐383 in this issue